He added that they were keeping a close watch on raw material prices.
“China is likely to keep prices competitive, as it is facing a 34 per cent tariff. With its massive capacities, it needs markets. So, raw material prices are likely to remain competitive,” he said.
The US has exempted imports of pharmaceuticals, energy, and certain minerals from reciprocal tariffs. However, Trump has said he plans to impose additional tariffs on pharmaceuticals. The quantum and timelines are not yet known.
Bhavin Mehta, vice-chairman of the Pharmaceuticals Export Promotion Council of India, echoed this view, saying raw material prices might stay competitive due to China’s excess capacities. “In the past two to three years, China has built huge active pharmaceutical ingredient capacities, and with the US market becoming a tough entry, it would need to sell its production somewhere. Hence, prices may remain competitive,” he explained.